Melanoma-associated antigen recognized by T cells (MART-1): The advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine-needle aspiration

Cancer

Volumn 87, Issue 1, 1999, Pages 37-42

  Fetsch, Patricia A ^a   Marincola, Francesco M ^a   Filie, Armando ^a   Hijazi, Yasmine M ^a   Kleiner, David E ^a   Abati, Andrea ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Fine needle aspiration; HMB 45; Immunocytochemistry; MART 1; Metastatic malignant melanoma

Indexed keywords

CELL MARKER;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; IMMUNOTHERAPY; MELANOMA; NEEDLE BIOPSY; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BIOPSY, NEEDLE; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOENZYME TECHNIQUES; MELANOMA; NEOPLASM PROTEINS; PARAFFIN EMBEDDING; SENSITIVITY AND SPECIFICITY; SOFT TISSUE NEOPLASMS;

EID: 0033602060     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990225)87:1<37::AID-CNCR7>3.0.CO;2-7     Document Type: Article

References (32)

1. Colombari R, Bonetti F, Zamboni G, Scarpa A, Marino F, Tomezzoli A, et al. Distribution of melanoma specific antibody (HMB45) in benign and malignant melanocytic tumors. Virchows Archiv A Pathol Anat 1988;413:17-24.
2. Gown A, Vogel A, Hoak D, Gough F, McNutt M. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986;123:195-203.
3. Bacchi C, Bonetti F, Pea M, Martignoni G, Gown A. HMB-45: a review. Appl Immunohistochem 1996;4:73-85.
4. Wick M, Swanson P, Racamora A. Recognition of malignant melanoma by monoclonal antibody HMB45: an immunohistochemical study of 200 paraffin embedded cutaneous tumors. J Cutan Pathol 1988;15:201-7.
5. Kawakami Y, Eliyahu S, Delgado C, Robbins P, Rivoltini L, Topalian S, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T-cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91: 3515-9.
6. Kawakami Y, Eliyahu S, Delgado C, Robbins P, Sakaguchi K, Appella E, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91: 6458-62.
7. Chen Y-T, Stockert E, Jungbluth A, Tsang S, Coplan K, Scanlan M, et al. Serological analysis of Melan-A (MART-1), a melanocyte-specific protein homogenously expressed in human melanomas. Proc Natl Acad Sci USA 1996;93: 5915-9.
8. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52.
9. Coulie P, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
10. Kawakami Y, Battles J, Kobayashi T, Wang X, Tupesis J, Marincola F, et al. Production of recombinant MART-1 proteins and specific anti-MART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. J Immunol Methods 1997;202:13-25.
11. Marincola F, Hijazi Y, Fetsch P, Salgaller M, Rivoltini L, Cormier J, et al. Analysis of the melanoma associated antigens MART-1 and GP-100 in metastatic melanoma. J Immunother 1996;19:192-205.
12. Rosenberg S, White D. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother 1996;19: 81-4.
13. Cormier J, Hijazi Y, Abati A, Fetsch P, Bettinotti M, Steinberg S, et al. Heterogenous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998;75:517-24.
14. Fetsch P, Cormier J, Hijazi Y. Immunocytochemical detection of MART-1 in fresh and paraffin embedded malignant melanomas. J Immunother 1997;20:60-4.
15. Kageshita R, Kawakami Y, Hirai S, Ono T. Differential expression of MART-1 in primary and metastatic melanoma lesions. J Immunother 1997;20:460-5.
16. Nicotra M, Nistico P, Mangoni A, Di Filippo F, Marincola F, Natali P. Melan-A/MART-1 antigen expression in cutaneous and ocular melanomas. J Immunother 1997;20:466-9.
17. Rodriguez-Soto J, Warnke R, Rouse R. Endogenous avidin-binding activity in paraffin-embedded tissue revealed after microwave treatment. Appl Immunohistochem 1997;5:59-62.
18. Metcalf J. Melanoma: criteria for histological diagnosis and its reporting. Semin Oncol 1996;23:688-92.
19. Ordonez N, Xiaolong J, Hickey R. Comparison of HMB-45 monoclonal antibody and S-100 protein in the immunohistochemical diagnosis of melanoma. Am J Clin Pathol 1988; 90:385-90.
20. Azumi N, Battifora H. The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms: a comprehensive immunohistochemical study on formalin- and alcohol-fixed tumors. Am J Clin Pathol 1987;88: 286-96.
21. Beaty M, Fetsch P, Wilder A, Marincola F, Abati A. Effusion cytology of malignant melanoma: a morphologic and immunocytochemical analysis including application of the MART-1 antibody. Cancer Cytopathol 1997;81:57-63.
22. Miettinen M, Franssila K. Immunohistochemical spectrum of malignant melanoma: the common presence of keratins. Lab Invest 1996;61:623-8.
23. Fetsch P, Marincola F, Abati A. Cytokeratin positivity in fine needle aspirates of metastatic malignant melanoma: fact or fiction? Diagn Cytopathol. In press.
24. Bonetti F, Pea M, Martignoni G, Mombello A, Colombari R, Zambini G, et al. False-positive immunostaining of normal epithelia and carcinomas with ascites fluid preparations of antimelanoma monoclonal antibody HMB-45. Am J Clin Pathol 1991;95:454-9.
25. Hoon V, Thung S, Kaneko M, Unger P. HMB-45 reactivity in renal angiomyolipoma and lymphangioleiomyomatosis. Arch Pathol Lab Med 1994;118:732-4.
26. Fetsch P, Fetsch J, Marincola F, Travis W, Batts K, Abati A. Comparison of melanoma antigen recognized by T cells (MART-1) to HMB-45: additional evidence to support a common lineage for angiomyolipoma, lymphangiomyomatosis, and clear cell sugar tumor. Mod Pathol 1998;11:699-703.
27. Pea M, Bonetti F, Zamboni G, Martignoni G, Riva M, Colombari R, et al. Melanocyte marker HMB-45 is regularly expressed in angiomyolipoma of the kidney. Pathology 1991; 23:185-8.
28. Bonetti F, Pea M, Martignoni G, Doglioni C, Zamboni G, Capelli P, et al. Clear cell ("sugar") tumor of the lung is a lesion strictly related to angiomyolipoma: the concept of a family of lesions characterized by the presence of the perivascular epithelioid cells (PEC). Pathology 1994;26: 230-6.
29. Zamboni G, Pea M, Martignoni G, Zancanaro C, Faccioli G, Gilioli E, et al. Clear cell "sugar" tumor of the pancreas. Am J Surg Pathol 1996;20:722-30.
30. Gal A, Koss M, Hochholzer L, Chejfec G. An immunohistochemical study of benign clear cell ("sugar") tumor of the lung. Arch Pathol Lab Med 1991;115:1034-8.
31. Busam K, Iversen K, Coplan K, Old L, Stockert E, Chen Y-T, et al. Immunoreactivity for A103, an antibody to Melan-A (Mart-1), in adrenocortical and other steriod tumors. Am J Surg Pathol 1998;22:57-63.
32. Jungbluth A, Busam K, Gerald W, Stockert E, Coplan K, Iversen K, et al. An anti-Melan-A monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Am J Surg Pathol 1998;22:595-602.